International and russian experience in treating children’s flu
https://doi.org/10.21518/2079-701X-2018-17-137-145
Abstract
The article presents an extensive clinical experience about the treatment and prevention of influenza by oseltamivir for children and adults including high-risk group patients through different countries around the world over the past 17 years. The article reveals the causes of resistance to oseltamivir with a relative evolution proportion. The new domestic drug Nomides (oseltamivir), which manufactured by Pharmasintez JSC (Russia) in accordance with the Good Manufacturing Practice (GMP), has been represented in the article by unique dosage forms 30 and 45 mg on the Russian market for childrens older than one years old.
About the Authors
V. F. Uchaikin
Pirogov Russian National Research Medical University of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
O. V. Kladova
Pirogov Russian National Research Medical University of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
F. S. Kharlamova
Pirogov Russian National Research Medical University of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
N. L. Valts
Morozov Children’s City Clinical Hospital of the Moscow Department of Health
Russian Federation
Moscow
Russian Federation
Moscow
Yu. V. Kompaniets
Morozov Children’s City Clinical Hospital of the Moscow Department of Health
Russian Federation
Moscow
Russian Federation
Moscow
N. L. Grishkevich
Morozov Children’s City Clinical Hospital of the Moscow Department of Health
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Federal Service for Oversight of Consumer Protection and Welfare Available at: http://www.rospotrebnadzor.ru.
2. Office for National Statistics Available at: http://www.gks.ru.
3. On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2017: State report. M.: Federal Service for Supervision of Consumer Rights Protection and Human Welfare, 2018. 268 p.
4. Enserink M. Bird flu infected 1000, Dutch researchers say. Science, 2004, 306: 590b.
5. Clinical guidelines. Influenza in children. AVI MOO of St. Petersburg and Leningrad region, Eurasian Society for Infectious Diseases MOO, 2017: 43.
6. Kopcha VS, Bondarenko AN. Influenza: pneumonia or pulmonary edema? Features of pathogenesis and treatment. Zdravookhranenie (Minsk), 2011, 2: 44-49.
7. Sergienko EN, Germanenko IG, Yasinskaya LI, Valkovich EM. Influenzaassociated central nervous system dysfunction. Meditsinskaya Panorama, 2012, 1: 10-13.
8. Germanenko IA, Sergienko EN, Kletsky SK, Puchkov AF. Pathomorphological manifestations of influenza infection in children. Issues of pathological diagnosis of modern infections and other diseases: a collection of research articles of the 2nd Congress of Anatomical Pathologists of the Republic of Belarus. 2011: 60-61.
9. Uchaikin VF, Nisevich NI, Shamsheva OV. Infectious diseases and vaccine prophylaxis in children. M.: Uchebnoe Izdanie, 2006, 687 p.
10. Loughlin J, Poulios N, Napalkov P, et al. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics, 2003, 21(4): 273-283.
11. O’Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics, 2004, 113(3 Pt 1): 585-593.
12. Prozorkina HV, Rubashkina PA. Fundamen tals of microbiology, virology and immunology. 2002
13. Van Essen GA, Palache AM, Forleo E, Fedson DS. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine, 2003, 21: 1780-85.
14. Thomas R, Jefferson T, Demicheli V. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev, 2005, 2: CD 005187.
15. Deeks JJ, Higgins JPT, Altman DG. Ana lysing and presenting results. In: Alderson P, Green S, Higgins J, eds. Cochrane reviewer`s handbook 4.2.2. Chichester: John Wiley & Sons, 2004.
16. Wells GA, Shea BO, Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in metaanalyses. http: // www.ohri.ca/programs/clinicalepidemiology/oxfordweb.htm (accessed Sept 2,2005).
17. RevMan Analyses. Version 1.0 for Windows. In: Review manager (RevMan) 4.2. Oxford: The Cochrane Collaboration, 2003.
18. Stephenson I et al. Neuraminidase Inhibitor Resistance after OseltamivirTreatment of Acute Influenza A and B in Children. Clinical Infectious Diseases, 2009, 48: 389-396.
19. Kolbin AS, Ivanyuk AB, Kharchev AV. Oseltamivir in paediatric practice (global experience). Pediatricheskaya Farmakologia, 2008, 5 (6): 16-21.
20. Oxford JS et al. Targeting influenza virus neuraminidase. a new strategy for antiviral therapy. Drug Dis Today, 1998, 3(10): 448–456.
21. Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet, 2004, 364: 759–65.
22. Nicholson KG, Aoki FY, Osterhaus ADME, et al. Treatment of acute influenza: efficacy and safety of the oral neuraminidase inhibitor oseltamivir. Lancet, 2000, 355: 1845–50.
23. Treanor JJ, Hayden FG,Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA, 2000, 283: 1016–24.
24. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized, controlled trials for prevention and treatment. JAMA, 1999, 282: 1240–6.
25. Yen H-L, Monto As, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis, 2005, 192: 665–672.
26. World Health Organization. Influenza vaccines. Wkly Epidemiol Rec, 2000, 75: 281–8.
27. World Health Organization. Influenza vaccines. Wkly Epidemiol Rec, 2002: 77: 229.
28. Kladova OV, Pogodina TF, Uchaikin VF. Experience in using oseltamivir (tamiflu) to treat influenza and ARVI in children. Praktika Pediatra, 2007, 2: 6-10.
29. Kladova OV, Pogodina TF, Zamakhina EV, Uchaikin VF. The problem of flu today and tomorrow. Detskie Infektsii, 2007, 1: 17-20.
30. Osidak LV, Zarubaev VV, Afanasyeva OI, Voloshchuk LV, Gonchar VV, Pisareva MM, et al. Oseltamivir: antiviral therapy for influenza A (H1N1) pdm09 in children and adults. Detskie Infektsii, 2016: 19-24.
31. Garg S, Fry AM, Patton M, Fiore AE, Finelli L. Antiviral treatment of influenza in children. Pediatr Infect Dis J, 2012 Feb, 31(2): 43-51.
32. Calfee DP, Peng AW, Cass LMR et al. Protective efficacy of intravenous zanamivir in experimental human influenza A virus infection. Antimicrobial Agents and Chemotherapy, 2004, 43: 1616-20.
33. Hayden FG, Osterhaus AD, Treanor JUJ et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza А virus infections. GC167 Influenza Study Group. New England Journal of Medicine, 1997, 337: 874-80.
34. Singh S, Barghoorn J, Bagdonas A et al. Clinical benefits with oseltamivir in treating influenza in abuit populations. Clinical Drug Investigation, 2003, 23: 561-9.
35. Guidelines for the diagnosis and treatment of influenza. M., 2016. p. 29
36. Graner S et al. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. BMJ, 2017: 356.
37. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA, editors. Options for the Control of Influenza. New York, Alan R. Liss Inc., 1986: 155–68.
38. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA, 1985, 253: 1136–9.
39. Palache AM. Influenza vaccines. A reappraisal of their use. Drugs, 1997, 54: 841–56.
40. Shun-Shin M, Thompson M, Heneghan C et al. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ, 2009, 339: b3172, doi: 10.1136/bmj.b3172.
41. Burch J, Stock C et al. Prescription of anti-influenza drugs for healthy adults: a systemic review and meta-analysis. Lancet Infect Dis, 2009. doi: 10.1016/S1473-3099(09)70199-9.
42. WHO. Antiviral drugs for pandemic flu (H1N1) 2009: definitions and use. http://www.who.int/csr/disease/swineflu/frequently_asked_questions/antivirals/definitions_use/ru/
43. Thompson WW, Weintraub E, Dhankhar P, Cheng OY, Brammer L, Meltzer MI, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respi Viruses, 2009, 3: 37-49.
44. Nair H, Abdullah Brooks W, Katz M et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet, 2011, 378: 1917–3.
45. Global Alert and Response (GAR) Diseases covered by our activities. Pandemic Flu (H1N1) 2009. Short Message
46. CDC H1N1 Flu. Questions and Answers: Antiviral Drugs, 2009–2010 Flu Season.
47. CDC – Seasonal Influenza (Flu) – Weekly Report: Influenza Summary Update. https:// www.cdc.gov/flu/weekly/weeklyarchives20092010/weekly52.htm.
48. State Register of Medicinal Products: Ministry of Health of the Russian Federation, 2000. (Internet version of the updated database dated January 17, 2002, on the website www.remedium.ru).
49. Winquist AG, Fukuda K, Bringes CB et al. Neuraminidase inhibitors for treatment of Influenza A and B infections. MMWR, 1999, 48(14): 1–9.
50. Update on oseltamivir resistance to influenza H1N1 (2009) viruses. World Health Organization (WHO), December 15, 2010.
Review
For citations:
Uchaikin VF, Kladova OV, Kharlamova FS, Valts NL, Kompaniets YV, Grishkevich NL. International and russian experience in treating children’s flu. Meditsinskiy sovet = Medical Council. 2018;(17):137-145. (In Russ.) https://doi.org/10.21518/2079-701X-2018-17-137-145
Views:
930
Email this article 